Business Context and Reporting Period
Tenon Medical, Inc. (TNON), an emerging growth company incorporated in Delaware, filed this Form 8-K on August 27, 2026, reporting a material definitive agreement and unregistered sales of equity securities. The company is based in Los Gatos, California, and its common stock and warrants trade on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Details
The company completed a private placement that closed on August 31, 2026. Key financial terms include:
- Gross Proceeds: $2,999,404.59 received upon closing.
- Additional Potential Proceeds: $597.61 receivable upon exercise of Pre-Funded Warrants.
- Securities Issued:
- 597,610 Pre-Funded Warrants at $5.019 per warrant.
- 1,058,517 Series A Warrants with an exercise price of $5.02 per share.
- Placement Agent Fees: 7% of aggregate gross proceeds paid to WallachBeth Capital LLC.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels prior to this transaction.
Material Changes and Use of Proceeds
This transaction represents a significant capital raise event. The company intends to use the net proceeds for the following purposes:
- Repayment of certain debt.
- Working capital.
- General corporate purposes.
There are no comparative financial metrics provided in this filing to assess changes versus prior periods.
Outlook, Risks, and Contingencies
Warrant Terms and Restrictions:
- Series A Warrants: Immediately exercisable, expiring five years from issuance. Exercise is restricted if the purchaser would own more than 4.99% of outstanding common stock (increasable to 9.99% with 61 days' notice).
- Pre-Funded Warrants: Immediately exercisable at $0.001 per share. Exercise is restricted if the purchaser would own more than 9.99% of outstanding common stock.
Registration Rights: The company agreed to file a registration statement for the resale of the warrant shares within 15 days of the agreement (August 31, 2026) and use best efforts to have it declared effective within 45 days (or 75 days in the event of a full SEC review).
Risks: The issuance relies on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D. Dilution may occur upon the exercise of warrants, subject to the ownership caps described above.
Investor Verification Checklist
- Verify the exact amount of debt to be repaid with the net proceeds.
- Confirm the current outstanding share count to calculate the precise dilution impact of the 1,656,127 total warrant shares.
- Monitor the status of the registration statement filing and its effectiveness date as required by the Registration Rights Agreement.
- Review the company's cash position post-closing to assess runway for working capital needs.